Index of /template_files/1402/PR
Name
Last modified
Size
Description
Parent Directory
-
Virpax Pharmaceuticals Reports 2021 Third Quarter Final 11.15.2021 w logo.pdf
22-Feb-2023 18:17
345K
Virpax Earnings Release 2nd Qtr Final 08.10.2021.pdf
22-Feb-2023 18:17
308K
Virpax Earnings Release Final 05-18-21.pdf
22-Feb-2023 18:17
289K
2021.10.06 Virpax Signs Agreement to Initiate IND Studies for AnQlar1.pdf
22-Feb-2023 18:17
229K
Virpax_MMS019 InVivo Data 04.19.2021 Final w logo.pdf
22-Feb-2023 18:17
213K
2021.03.22 Virpax to Initiate IND Enabling Studies Probudur.pdf
22-Feb-2023 18:17
209K
2021.03.10 Virpax to Initiate IND Enabling Studies Epoladerm.pdf
22-Feb-2023 18:17
205K
2021.02.16 Virpax Pharmaceuticals Announces Pricing of Initial Public Offering.pdf
22-Feb-2023 18:17
203K
2021.02.23 Virpax_Envelta - IND Enabling Studies Annoucement.pdf
22-Feb-2023 18:17
200K
2021.12.20 VRPX Announces Clinical Trial Site in Canada for FIH Study of Epoladerm.pdf
22-Feb-2023 18:17
194K
2020.04.28 VIRPAX New Board Member_Jacob.pdf
22-Feb-2023 18:17
193K
2021.04.05 Virpax_Probudur demonstrates minimal local nerve toxicity.pdf
22-Feb-2023 18:17
192K
2020.03.19 PIND OSF200 Virpax Pharmaceuticals.pdf
22-Feb-2023 18:17
191K
VirpaxReportsFavorablePreclinicalSafetyDataforEnvelta.pdf
22-Feb-2023 18:17
190K
Virpax Strengthens Board of Directors 07.30.21 Final w Logo.pdf
22-Feb-2023 18:17
187K
2020.07.09 Vanila Singh Elected to Virpax Pharmaceuticals BOD.pdf
22-Feb-2023 18:17
186K
2020.02.05 Virpax Pharmaceuticals SOMSA DSF100 and NES100 Final.pdf
22-Feb-2023 18:17
177K
2021.02.19 Virpax Pharmaceuticals Announces Closing of Initial Public Offering.pdf
22-Feb-2023 18:17
176K
2022.01.04 Virpax to Present at H.C. Wainwright BioConnect Virtual Conference Final.pdf
22-Feb-2023 18:17
175K
2020.06.02 Virpax Pharmaceuticals Announces Appt of Chris Chipman CFO.pdf
22-Feb-2023 18:17
171K
VRPX Follow On Press Release Pricing 4834-8259-7114 Final 09.14.2021 w. logo.pdf
22-Feb-2023 18:17
168K
Virpax Announces Successful Completion of Its Dermal Safety Trials for Epoladerm Final.pdf
22-Feb-2023 18:17
165K
Envelta IND enabling studies - expanded indications Final 06.21.2021 w.logo.pdf
22-Feb-2023 18:17
165K
2021.12.08 VRPX Reports Successful Results of Tox Pharmacokinetic Studies Epoladerm.pdf
22-Feb-2023 18:17
165K
2018.12.27 Virpax announces Successful PIND Meeting for LBL100.pdf
22-Feb-2023 18:17
164K
VRPX Announces Closing of $40 Million Public Offering of Common Stock w. logo .pdf
22-Feb-2023 18:17
163K
2020.01.14 Virpax to Develop Its MET Intranasal Enkephalin Formulation 01.14.2020.pdf
22-Feb-2023 18:17
159K
2020.08.24 Virpax Pharma to Develop MMS019.pdf
22-Feb-2023 18:17
159K
2019.04.16 Virpax Licenses MET Intranasal Formulation from Nanomerics.pdf
22-Feb-2023 18:17
159K
Virpax Continues to Advance Envelta Development Under CRADA 11.10.2021 Final w.logo.pdf
22-Feb-2023 18:17
157K
2020.08.31 NES100 Virpax Pharmaceuticals Enters into CRADA for NES100.pdf
22-Feb-2023 18:17
157K
2020.03.02 PIND NES100 Virpax Pharmaceuticals Final.pdf
22-Feb-2023 18:17
157K
2020.12.08 MMS019 inhibits SARS-COV-2.pdf
22-Feb-2023 18:17
157K
2021.12.28 Virpax Pharmaceuticals Recaps Milestones and Highlights Product Portfolio.pdf
22-Feb-2023 18:17
156K
2019.09.10 VIRPAX BOD Appointment Final.pdf
22-Feb-2023 18:17
153K
2021.08.17 Virpax Receives FDA Response and Guidance on MMS019.pdf
22-Feb-2023 18:17
153K
Virpax Announces Poster Presentation for Envelta at PAINWeek 2021.pdf
22-Feb-2023 18:17
151K
Virpax Announces MMS019 Manufacturing and Supply Agreement 08.26.2021 w.logo.pdf
22-Feb-2023 18:17
151K
LD Micro Conference_Virpax Press Release Final 06.02.2021 Logo.pdf
22-Feb-2023 18:17
151K
2019.09.17 VIRPAX Appointment Gerald Bruce Final.pdf
22-Feb-2023 18:17
151K
Virpax Provides Progress Update on Product Candidates Final 07.07.2021.pdf
22-Feb-2023 18:17
147K
Virpax to Develop Intranasal Cannabidiol Product for the Management of Epilepsy 09.20.2021 w logo.pdf
22-Feb-2023 18:17
145K
Torreya_Virpax Press Release Final w.logo 04.22.2021.pdf
22-Feb-2023 18:17
144K
2019.04.24 Virpax to Present at ThinkEquity Conference.pdf
22-Feb-2023 18:17
144K
2021.10.01 Virpax to Present at the NobleCon Online Pain Management Investor Forum.pdf
22-Feb-2023 18:17
142K
2021.03.02 Virpax Pharmaceuticals Announces Newly Issued Patent for Probudur.pdf
22-Feb-2023 18:17
129K
2019.06.03 Virpax selected for Two Presentations at the 2019 MHSRS.pdf
22-Feb-2023 18:17
129K
2019.08.06 Virpax to Present at 2019 MHSRS.pdf
22-Feb-2023 18:17
86K
2018.09.12 Virpax Reports Pre-IND Guidance From FDA for DSF100.pdf
22-Feb-2023 18:17
44K
Apache/2.2.14 (Ubuntu) Server at preview.irdirect.net Port 80